SS Innovations International, Inc. (NASDAQ: SSII) has reported significant growth in the utilization and global reach of its SSi Mantra surgical robotic system, underscoring the company's accelerating traction in the competitive robotic surgery market. According to the company's latest update, cumulative procedures using the SSi Mantra reached 14,103 as of Sept. 8, 2026, representing a 79% increase from 7,885 at the end of 2025. Concurrently, the installed base of systems grew 42% to 238 units, up from 168 at year-end 2025. These figures highlight not only rising adoption but also deeper clinical integration, as approximately 1,500 physicians have been trained on the platform and the system has been used across more than 170 types of surgical procedures.
The expansion into new international markets marks a critical step in SS Innovations' strategy to democratize robotic surgery. Recent milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra system in Sri Lanka, and the first telesurgery procedure within the Philippines. These developments demonstrate the system's versatility and its potential to address unmet surgical needs in both emerging and established healthcare markets. The company also reported 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of Aug. 31, including a notable more than 13,600-mile telesurgery between Colombia and India. This long-distance procedure exemplifies the platform's advanced teleoperation capabilities, which could extend specialized surgical expertise to remote or underserved regions.
Operational efficiency gains are also evident. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India, showcasing the system's reliability and high-throughput potential. Such performance metrics are likely to appeal to hospitals seeking to maximize their investment in robotic surgery programs while maintaining high standards of patient care.
Looking ahead, SS Innovations anticipates two major regulatory catalysts. The company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. Additionally, it believes European Union CE marking certification can be obtained by year-end 2026. Successful clearance in these key markets would significantly broaden the company's addressable market and lend further credibility to its technology, potentially accelerating adoption among U.S. and European healthcare providers.
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company's product range includes its proprietary "SSi Mantra" surgical robotic system and its comprehensive suite of "SSi Mudra" surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
For investors, the latest operational and regulatory updates provide tangible evidence of SS Innovations' execution against its growth strategy. The substantial year-over-year increase in procedures and installations suggests that the SSi Mantra is gaining acceptance among surgeons and healthcare institutions. Moreover, the impending FDA and CE marking decisions could serve as near-term catalysts, potentially unlocking new revenue streams and strengthening the company's competitive position against larger, established players in the robotic surgery space. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. To view the full report, visit https://ibn.fm/DJILj.
